No­var­tis’ Leqvio cuts LDL lev­els by 50% over three years: #ESC23

No­var­tis said that 78.4% of pa­tients in a Phase III met a pre-spec­i­fied low-den­si­ty lipopro­tein cho­les­terol tar­get af­ter tak­ing the siR­NA cho­les­terol drug Leqvio for three years, with pa­tients re­port­ing a 49.4% de­crease, on av­er­age, in their LDL lev­els over the same pe­ri­od of time.

The Swiss drug­mak­er un­veiled the da­ta Mon­day at the Eu­ro­pean So­ci­ety of Car­di­ol­o­gy meet­ing in Am­s­ter­dam. ORI­ON-8 is a com­bi­na­tion, open-la­bel ex­pan­sion study that re­cruit­ed 3,274 pa­tients from four pre­vi­ous tri­als as part of the com­pa­ny’s Leqvio clin­i­cal re­search pro­gram, called Vic­tO­RI­ON.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER